Citation
Gaber, Charles E.; Shaheen, Nicholas J.; Edwards, Jessie K.; Sandler, Robert S.; Nichols, Hazel B.; Sanoff, Hanna K.; & Lund, Jennifer L. (2022). Trimodality Therapy vs Definitive Chemoradiation in Older Adults with Locally Advanced Esophageal Cancer. JNCI Cancer Spectrum, 6(6), pkac069. PMCID: PMC9623425Abstract
BACKGROUND: The comparative effectiveness of trimodality therapy vs definitive chemoradiation for treating locally advanced esophageal cancer in older adults is uncertain. Existing trials lack generalizability to older adults, a population with heightened frailty. We sought to emulate a hypothetical trial comparing these treatments using real-world data.METHODS: A cohort of adults aged 66-79 years diagnosed with locally advanced esophageal cancer between 2004 and 2017 was identified in the Surveillance Epidemiology and End Results-Medicare database. The clone-censor-weight method was leveraged to eliminate time-related biases when comparing outcomes between treatments. Outcomes included overall mortality, esophageal cancer-specific mortality, functional adverse events, and healthy days at home.
RESULTS: A total of 1240 individuals with adenocarcinomas and 661 with squamous cell carcinomas were identified. For adenocarcinomas, the standardized 5-year risk of mortality was 73.4% for trimodality therapy and 83.8% for definitive chemoradiation (relative risk [RR] = 0.88, 95% confidence interval [CI] = 0.82 to 0.95). Trimodality therapy was associated with mortality risk reduction for squamous cell carcinomas (RR = 0.87, 95% CI = 0.70 to 1.01). The 1-year incidence of functional adverse events was higher in the trimodality group (adenocarcinomas RR = 1.40, 95% CI = 1.22 to 1.65; squamous cell carcinomas RR = 1.21, 95% CI = 1.00 to 1.49). Over 5 years, trimodality therapy was associated with 160 (95% CI = 67 to 229) and 177 (95% CI = 51 to 313) additional home days in individuals with adenocarcinomas and squamous cell carcinomas, respectively.
CONCLUSIONS: Compared with definitive chemoradiation, trimodality therapy was associated with reduced mortality but increased risk of function-related adverse events. Discussing these tradeoffs may help optimize care plans.
URL
http://dx.doi.org/10.1093/jncics/pkac069Reference Type
Journal ArticleYear Published
2022Journal Title
JNCI Cancer SpectrumAuthor(s)
Gaber, Charles E.Shaheen, Nicholas J.
Edwards, Jessie K.
Sandler, Robert S.
Nichols, Hazel B.
Sanoff, Hanna K.
Lund, Jennifer L.
Article Type
RegularPMCID
PMC9623425Continent/Country
United States of AmericaState
NonspecificRace/Ethnicity
BlackWhite
Hispanic